6125 results
Heart & lung : the journal of critical care,
Volume 69, 17 3 2024, Pages 31-39
Modifiable risk factors and motivation for lifestyle change of CVD patients starting cardiac rehabilitation: The BENEFIT study.
Breeman LD, Pérez-Alonso A, Kühling-Romero D, Kraaijenhagen RA, Al-Dhahir I, IJzerman RVH, van Eersel R, Wolstencroft K, Bonten TN, Atsma DE, Chavannes NH, van Gemert-Pijnen L, Kemps HMC, Scholte Op Reimer W, Evers AWM, Janssen VR, BENEFIT consortium
Background: To improve lifestyle guidance within cardiac rehabilitation (CR), a comprehensive understanding of the motivation and lifestyle-supporting needs of patients with cardiovascular disease (CVD) is required. Objectives: This study's purpose is to evaluate patients' lifestyle and their motivation, self-efficacy and social support for change when starting CR. Methods: 1782 CVD patients (69 % male, mean age 62 years) from 7 Dutch outpatient CR centers participated between 2020 and...
Abstract
Cited 2 times since 2024 (4.5 per year)
source: EuropePMC
Nature medicine,
Volume 30, Issue 11, 16 3 2024, Pages 3223-3235
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could be an option and what the benefit of combination ICI could be. The adaptive BELLINI trial explored whether short combination ICI induces immune activation (primary end point, twofold increase in CD8+ T cells or IFNG), providing a rationale for neoadjuvant ICI without chemotherapy. Here, in...
Abstract
Cited 1 times since 2024 (2.2 per year)
source: EuropePMC
Communications biology,
Volume 7, Issue 1, 13 2 2024, Pages 1135
Nucleolus and centromere Tyramide Signal Amplification-Seq reveals variable localization of heterochromatin in different cell types.
Kumar P, Gholamalamdari O, Zhang Y, Zhang L, Vertii A, van Schaik T, Peric-Hupkes D, Sasaki T, Gilbert DM, van Steensel B, Ma J, Kaufman PD, Belmont AS
Genome differential positioning within interphase nuclei remains poorly explored. We extended and validated Tyramide Signal Amplification (TSA)-seq to map genomic regions near nucleoli and pericentric heterochromatin in four human cell lines. Our study confirmed that smaller chromosomes localize closer to nucleoli but further deconvolved this by revealing a preference for chromosome arms below 36-46 Mbp in length. We identified two lamina associated domain subsets through their differential nucl...
Abstract
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
Volume 68, Issue 6, 11 2 2024, Pages 815-816
Editor's Choice - Radiation Protection and Pregnancy in Vascular Surgery and Interventional Radiology in the Netherlands.
Jongen JMJ, Samim M, Hoornstra KJPC, Eefting D, van Herwaarden JA, Blok JJ
Abstract
Cited 1 times since 2024 (2.2 per year)
source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation,
Volume 32, Issue 10, 10 2 2024, Pages 338-345
2023 European Society of Cardiology guidelines for the management of acute coronary syndromes : Statement of endorsement by the NVVC.
Zwart B, Claessen BEPM, Damman P, Woudstra P, Vink MA, Balder JW, Dickinson MG, Badings EA, Appelman Y, van 't Hof AWJ, Ten Berg JM, Arslan F
This review discusses the new recommendations in the 2023 European Society of Cardiology guidelines on the management of acute coronary syndrome and provides a perspective on topics specific to clinical practice in the Netherlands, including pre-treatment, antiplatelet agent strategies, the use of risk scores and logistical considerations with regard to the timing of coronary angiography.
Abstract
Atherosclerosis,
Volume 398, 7 1 2024, Pages 118595
Arterial inflammation on [<sup>18</sup>F]FDG PET/CT in melanoma patients treated with and without immune checkpoint inhibitors: CHECK-FLAME I.
Polomski EAS, Kapiteijn EW, Heemelaar JC, van der Kolk AV, Kalisvaart TM, van de Burgt A, Dibbets-Schneider P, van Velden FHP, Seijkens TTP, Stöger JL, Jukema JW, de Geus-Oei LF, Antoni ML
Background and aims: Immune checkpoint inhibitors (ICIs) revolutionized cancer treatment. However, ICIs may increase the immune response to non-tumor cells, possibly resulting in increased arterial inflammation, raising the risk of atherosclerotic events. Nevertheless, malignancies may induce a pro-inflammatory state and the association between ICIs and arterial inflammation remains to be clarified. This study aims to assess differences in increase in arterial inflammation between patients with...
Abstract
Heart rhythm,
6 1 2024, Pages S1547-5271(24)03288-0
Lesion delivery and scar formation in catheter ablation for atrial fibrillation: The DECAAF II trial.
Akoum N, Mekhael M, Bisbal F, Wazni O, McGann C, Lee H, Bardsley T, Greene T, Dean JM, Dagher L, Kholmovski E, Mansour M, Marchlinski F, Wilber D, Hindricks G, Mahnkopf C, Wells D, Jaïs P, Sanders P, Brachmann J, Bax JJ, Morrison-de Boer L, Deneke T, Calkins H, Sohns C, Marrouche N, DECAAF II investigators
Background: The Efficacy of Delayed Enhancement MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation randomized trial showed no difference in atrial fibrillation (AF) recurrence with additional delayed enhancement magnetic resonance imaging (DE-MRI) fibrosis-targeted ablation to pulmonary vein isolation (PVI) in persistent AF. Objective: We evaluated the effect of lesion delivery on ablation-induced scarring and AF recurrence. Methods: Lesions delivered, targetin...
Abstract
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists,
5 1 2024, Pages 15266028241274568
Maximal Systolic Acceleration and Near-Infrared Fluorescence Imaging With Indocyanine Green as Predictors for Successful Lower Extremity Revascularization.
Kruiswijk MW, Willems SA, Koning S, Tange FP, J W M Brouwers J, Peul RC, van Schaik J, Schepers A, Hamming J, van der Bogt KEA, van Rijswijk CSP, Vahrmeijer AL, van den Hoven P, van der Vorst JR
Background: Patients with lower extremity arterial disease (LEAD) frequently require revascularization procedures. Currently used diagnostic methods are insufficient in predicting successful outcomes and focus on macrovascular rather than microvascular state. Several promising modalities to increase diagnostic accuracy are emerging, including maximal systolic acceleration (ACCmax), measured by duplex ultrasound (DUS). For the assessment of tissue perfusion, near-infrared fluorescence (NIR) imagi...
Abstract
The Pediatric infectious disease journal,
Volume 44, Issue 1, 4 1 2024, Pages 83-89
Pediatric Varicella-related Hospitalization in Turkey Between 2008 and 2018: Impact of Universal Single Dose Varicella Vaccine (VARICOMP Study).
Dinleyici EC, Kurugol Z, Devrim I, Bayram N, Dalgic N, Yasa O, Tezer H, Ozdemir H, Ciftci E, Tapisiz A, Celebi S, Hacimustafaoglu M, Yilmaz D, Hatipoglu N, Kara A, VARICOMP Study Group
Background: A single-dose varicella vaccine at 12 months of age was introduced to the National Immunization Program in February 2013 in Turkey. This study aimed to evaluate varicella-related hospitalization in children and the impact of a single-dose live attenuated varicella vaccine over the first 5.5 years of introducing a universal varicella vaccination. Methods: We analyzed data collected from the medical records of children
Abstract
American heart journal,
Volume 278, 2 1 2024, Pages 61-71
Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: Rationale and design of the COL BE PCI trial.
De Cock E, Kautbally S, Timmermans F, Bogaerts K, Hanet C, Desmet W, Gurné O, Vranckx P, Hiltrop N, Dujardin K, Vanduynhoven P, Vermeersch P, Pirlet C, Hermans K, Van Reet B, Ferdinande B, Aminian A, Dewilde W, Guédès A, Simon F, De Roeck F, De Vroey F, Jukema JW, Sinnaeve P, Buysschaert I
Introduction: Patients with coronary artery disease (CAD) remain vulnerable to future major atherosclerotic events after revascularization, despite effective secondary prevention strategies. Inflammation plays a central role in the pathogenesis of CAD and recurrent events. To date, there is no specific anti-inflammatory medicine available with proven effective, cost-efficient, and favorable benefit-risk profile, except for colchicine. Initial studies with colchicine have sparked major interest i...
Abstract
Journal of the American College of Cardiology,
Volume 84, Issue 13, 1 1 2024, Pages 1178-1189
Temporal Trends in Takotsubo Syndrome: Results From the International Takotsubo Registry.
Schweiger V, Cammann VL, Crisci G, Gilhofer T, Schlenker R, Niederseer D, Chen S, Ebrahimi R, Wenzl F, Würdinger M, Citro R, Vecchione C, Gili S, Neuhaus M, Franke J, Meder B, Jaguszewski M, Noutsias M, Knorr M, Jansen T, D'Ascenzo F, Dichtl W, von Lewinski D, Burgdorf C, Kherad B, Tschöpe C, Sarcon A, Shinbane J, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Koenig W, Pott A, Meyer P, Roffi M, Banning A, Wolfrum M, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Napp LC, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, Gilyarova E, Shilova A, Gilyarov M, El-Battrawy I, Akin I, Poledniková K, Toušek P, Winchester DE, Massoomi M, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Hauck C, Paolini C, Bilato C, Kobayashi Y, Kato K, Ishibashi I, Himi T, Din J, Al-Shammari A, Prasad A, Rihal CS, Liu K, Schulze PC, Bianco M, Jörg L, Rickli H, Pestana G, Nguyen TH, Böhm M, Maier LS, Pinto FJ, Widimský P, Felix SB, Braun-Dul
Background: The perception of takotsubo syndrome (TTS) has evolved significantly over the years, primarily driven by increased recognition of acute complications and mortality. Objectives: This study aimed to explore temporal trends in demographic patterns, risk factors, clinical presentations, and outcomes in patients with TTS. Methods: Patients diagnosed with TTS between 2004 and 2021 were enrolled from the InterTAK (International Takotsubo) registry. To assess temporal trends, patients were d...
Abstract
Journal of the American College of Cardiology,
Volume 84, Issue 11, 1 1 2024, Pages 994-1006
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.
Zahger D, Schwartz GG, Du W, Szarek M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Jukema JW, Kiss RG, Harrington RA, Moriarty PM, Scemama M, Manvelian G, Pordy R, White HD, Zeiher AM, Fazio S, Geba GP, Steg PG, ODYSSEY OUTCOMES Investigators
Background: It is unknown whether clinical benefit of proprotein convertase subtilisin/kexin type 9 inhibitors is associated with baseline or on-treatment triglyceride concentrations. Objectives: This study sought to examine relations between triglyceride levels and the effect of alirocumab vs placebo on cardiovascular outcomes using prespecified and post hoc analyses of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab)...
Abstract
Cited 2 times since 2024 (4.1 per year)
source: EuropePMC
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,
Volume 29, Issue 39, 1 1 2024
Increased circulation of GII.17 noroviruses, six European countries and the United States, 2023 to 2024.
Chhabra P, Wong S, Niendorf S, Lederer I, Vennema H, Faber M, Nisavanh A, Jacobsen S, Williams R, Colgan A, Yandle Z, Garvey P, Al-Hello H, Ambert-Balay K, Barclay L, de Graaf M, Celma C, Breuer J, Vinjé J, Douglas A
We report an increase in GII.17 norovirus outbreaks and sporadic infections of acute gastroenteritis in Austria, Germany, France, Ireland, the Netherlands, England and the United States during the 2023/24 season. A decrease in GII.4 coincided with GII.17 prevalence increasing to between 17% and 64% of all GII detections. Overall, 84% of the GII.17 strains clustered closely with strains first reported in Romania in 2021 and two new sub-lineages were identified. Norovirus surveillance and molecula...
Abstract
Cited 1 times since 2024 (2.1 per year)
source: EuropePMC
European heart journal. Cardiovascular Imaging,
Volume 25, Issue 10, 1 1 2024, Pages 1351-1359
Pericoronary adipose tissue for predicting long-term outcomes.
van Rosendael SE, Kamperidis V, Maaniitty T, de Graaf MA, Saraste A, McKay-Goodall GE, Jukema JW, Knuuti J, Bax JJ
Aims: Pericoronary adipose tissue (PCAT) attenuation obtained by coronary computed tomography angiography (CCTA) has been associated with coronary inflammation and outcomes. Whether PCAT attenuation is predictive of major adverse cardiac events (MACE) during long-term follow-up is unknown. Methods and results: Symptomatic patients with coronary artery disease (CAD) who underwent CCTA were included, and clinical outcomes were evaluated. PCAT was measured at all lesions for all three major coronar...
Abstract
Cited 1 times since 2024 (2.1 per year)
source: EuropePMC
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography,
Volume 37, Issue 12, 1 1 2024, Pages 1188-1190.e3
Right Ventricular to Pulmonary Artery Coupling and Prognosis in Transthyretin Cardiac Amyloidosis.
Meucci MC, Laenens D, Lillo R, Lombardo A, Burzotta F, Stassen J, Debonnaire P, Claeys M, Donal E, Droogmans S, Cosyns B, Jurcut R, Pinto FJ, Brito D, Yedidya I, Van De Heyning C, Sturkenboom N, Graziani F, Ajmone Marsan N
Abstract
Cited 2 times since 2024 (4.1 per year)
source: EuropePMC
The New England journal of medicine,
Volume 392, Issue 5, 31 5 2024, Pages 438-449
Continuation versus Interruption of Oral Anticoagulation during TAVI.
van Ginkel DJ, Bor WL, Aarts HM, Dubois C, De Backer O, Rooijakkers MJP, Rosseel L, Veenstra L, van der Kley F, van Bergeijk KH, Van Mieghem NM, Agostoni P, Voskuil M, Schotborgh CE, IJsselmuiden AJJ, Van Der Heyden JAS, Hermanides RS, Barbato E, Mylotte D, Fabris E, Frambach P, Dujardin K, Ferdinande B, Peper J, Rensing BJWM, Timmers L, Swaans MJ, Brouwer J, Nijenhuis VJ, Overduin DC, Adriaenssens T, Kobari Y, Vriesendorp PA, Montero-Cabezas JM, El Jattari H, Halim J, Van den Branden BJL, Leonora R, Vanderheyden M, Lauterbach M, Wykrzykowska JJ, van 't Hof AWJ, van Royen N, Tijssen JGP, Delewi R, Ten Berg JM, POPular PAUSE TAVI Investigators, POPular PAUSE TAVI Investigators
Background: One third of patients undergoing transcatheter aortic-valve implantation (TAVI) have an indication for oral anticoagulation owing to concomitant diseases. Interruption of oral anticoagulation during TAVI may decrease the risk of bleeding, whereas continuation may decrease the risk of thromboembolism. Methods: We conducted an international, open-label, randomized, noninferiority trial involving patients who were receiving oral anticoagulants and were planning to undergo TAVI. Patients...
Abstract
Nature communications,
Volume 15, Issue 1, 30 5 2024, Pages 7551
Time-series sewage metagenomics distinguishes seasonal, human-derived and environmental microbial communities potentially allowing source-attributed surveillance.
Becsei Á, Fuschi A, Otani S, Kant R, Weinstein I, Alba P, Stéger J, Visontai D, Brinch C, de Graaf M, Schapendonk CME, Battisti A, De Cesare A, Oliveri C, Troja F, Sironen T, Vapalahti O, Pasquali F, Bányai K, Makó M, Pollner P, Merlotti A, Koopmans M, Csabai I, Remondini D, Aarestrup FM, Munk P
Sewage metagenomics has risen to prominence in urban population surveillance of pathogens and antimicrobial resistance (AMR). Unknown species with similarity to known genomes cause database bias in reference-based metagenomics. To improve surveillance, we seek to recover sewage genomes and develop a quantification and correlation workflow for these genomes and AMR over time. We use longitudinal sewage sampling in seven treatment plants from five major European cities to explore the utility of ca...
Abstract
Research and practice in thrombosis and haemostasis,
Volume 8, Issue 6, 30 5 2024, Pages 102558
Erratum to 'Performance of Risk Scores in Predicting Major Bleeding in Left Ventricular Assist Device (LVAD) Recipients: a Comparative External Validation. '[Res Pract Thromb Haemost. 2024;8:e102437].
van der Horst SFB, de Jong Y, van Rein N, Jukema JW, Palmen M, Janssen E, Bonneville EF, Klok FA, Huisman MV, Tops LF, den Exter PL
[This corrects the article DOI: 10.1016/j.rpth.2024.102437.].
Abstract
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,
Volume 104, Issue 4, 29 5 2024, Pages 655-663
Intravascular lithotripsy in heavily calcified chronic total occlusion: procedural and one-year clinical outcomes.
Oliveri F, van Oort MJH, Al Amri I, Bingen BO, Claessen BE, Dimitriu-Leen AC, Kefer J, Girgis H, Vossenberg T, van der F, Jukema JW, Montero-Cabezas JM
Background: Calcification within chronic total occlusions (CTO) is strongly associated with worse outcomes. Despite the excellent success and safety of intravascular lithotripsy (IVL) in heavily calcified lesions, evidence in CTO remains scarce. Aim: This study aimed to evaluate the procedural and long-term clinical outcomes of IVL in heavily calcified CTO. Methods: Patients who underwent IVL between 2019 and 2024 from an ongoing prospective multicenter registry were eligible for inclusion. Pati...
Abstract
Journal of the American Heart Association,
Volume 13, Issue 17, 29 5 2024, Pages e034760
Genome-Wide Interaction Analyses of Serum Calcium on Ventricular Repolarization Time in 125 393 Participants.
Young WJ, van der Most PJ, Bartz TM, Bos MM, Biino G, Duong T, Foco L, Lominchar JT, Müller-Nurasyid M, Nardone GG, Pecori A, Ramirez J, Repetto L, Schramm K, Shen X, van Duijvenboden S, van Heemst D, Weiss S, Yao J, Benjamins JW, Alonso A, Spedicati B, Biggs ML, Brody JA, Dörr M, Fuchsberger C, Gögele M, Guo X, Ikram MA, Jukema JW, Kääb S, Kanters JK, Lifelines Cohort Study, Lin HJ, Linneberg A, Nauck M, Nolte IM, Pianigiani G, Santin A, Soliman EZ, Tesolin P, Vaccargiu S, Waldenberger M, van der Harst P, Verweij N, Arking DE, Concas MP, De Grandi A, Girotto G, Grarup N, Kavousi M, Mook-Kanamori DO, Navarro P, Orini M, Padmanabhan S, Pattaro C, Peters A, Pirastu M, Pramstaller PP, Heckbert SR, Sinner M, Snieder H, Völker U, Wilson JF, Gauderman WJ, Lambiase PD, Sotoodehnia N, Tinker A, Warren HR, Noordam R, Munroe PB
Background: Ventricular repolarization time (ECG QT and JT intervals) is associated with malignant arrhythmia. Genome-wide association studies have identified 230 independent loci for QT and JT; however, 50% of their heritability remains unexplained. Previous work supports a causal effect of lower serum calcium concentrations on longer ventricular repolarization time. We hypothesized calcium interactions with QT and JT variant associations could explain a proportion of the missing heritability....
Abstract
